查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
介入性肿瘤学市场按设备/耗材、癌症类型、程序、最终用户和地区划分 - 预测至 2029 年
市场调查报告书
商品编码
1649593

介入性肿瘤学市场按设备/耗材、癌症类型、程序、最终用户和地区划分 - 预测至 2029 年

Interventional Oncology Market by Devices & Consumables, Procedures, Cancer, End User - Global Forecast to 2029
出版日期: | 出版商: MarketsandMarkets | 英文 456 Pages | 订单完成后即时交付

价格

介入性肿瘤学市场规模预计将从 2024 年的 27.5 亿美元成长到 2029 年的 42.4 亿美元，预测期内的复合年增长率为 9.0%。

介入性肿瘤学在过去十年中经历了显着的增长。微创技术的进步和癌症发生率的上升是这项繁荣的主要原因。最初，由于长期以来采用传统的手术方法治疗癌症，介入肿瘤学市场尚未充分开发。然而，TACE、TARE 和热感消融等介入治疗的安全性和有效性证据越来越多，导致人们对使用这些治疗方法的兴趣日益浓厚。这些手术比传统手术有许多优势，包括恢復时间更短、併发症更少、患者整体治疗效果更好。对无法手术的肿瘤（尤其是肝癌、肺癌和肾癌）的有效治疗的需求不断增长，正在推动市场成长。

研究范围
调查年份 2024-2029
基准年 2023
预测期 2024-2029
考虑单位 金额（美元）
部分 按设备/耗材、癌症类型、程序、最终用户和地区
目标区域 北美、欧洲、亚太地区、中东和非洲（海湾合作委员会国家、罗马尼亚、中东和非洲）

从器械及耗材来看，栓塞器械在介入性肿瘤领域中占有最高的市场占有率。因为它是微创癌症治疗中极为重要的工具，比传统手术方法具有压倒性的优势。这些装置减少或阻断流向肿瘤的血液，使肿瘤缺乏生长所需的氧气和营养。放射栓塞疗法（也称为栓塞治疗、TACE 和选择性内放射治疗）日益增长的趋势是由于其在治疗无法手术的癌症（尤其是肝癌）方面已证明有效，而肝癌是介入肿瘤学的一个主要关注点。随着栓塞剂（包括药物释放型珠和放射性微球）的改进，准确性和结果得到提高，这种情况变得越来越普遍。全球癌症发病率不断上升、人们对非侵入性治疗方案认识的不断提高以及向门诊治疗模式的转变等因素进一步促进了这些设备的使用日益增多。

根据癌症类型，肝癌在介入性肿瘤学领域占据最大的市场占有率，这主要是由于全球发病率不断增加、死亡率高以及迫切需要有效和微创治疗方案。肝细胞癌是最常见的肝癌类型，与慢性B型和C型肝炎感染、过量摄取和非酒精性脂肪肝盛行率增加等危险因子密切相关。介入性肿瘤学中的TACE、TARE和经皮消融等标靶治疗对治疗无法切除的肝癌有很高的疗效。与传统化疗相比，这些治疗方法可以局部控制肿瘤，降低全身毒性，并提高存活率。

根据程序，经导管动脉放射栓塞术（TARE），也称为选择性内放射治疗（SIRT），在介入肿瘤学领域占有最大的市场占有率，因为它在治疗原发性和续发性肝癌方面已被证明有效，而原发性和继发性肝癌占全球癌症相关死亡的大多数。在这种治疗方法中，将载有放射性同位素（最常见的是钇-90）的微球直接注射到为肿瘤供血的肝动脉中。 TARE局部发射辐射，有效杀死癌细胞，同时最大限度地减少全身辐射暴露并减少对周围健康组织的损害。由于它比传统化疗和体外放射治疗更安全、耐受性更好、副作用更少，因此越来越受欢迎。此外，TARE 可能对无法切除的肝细胞癌或结肠直肠癌肝转移患者特别有用，因为这些患者无法采用替代疗法或无法获得替代疗法。

本报告研究了全球介入肿瘤学市场，并按设备/耗材、癌症类型、程序、最终用户、区域趋势和公司概况对市场进行了详细分析。

目录

第 1 章 简介

第二章调查方法

第三章执行摘要

第 4 章重要考察

第五章 市场概况

  • 介绍
  • 市场动态
  • 产业趋势
  • 价值链分析
  • 技术分析
  • 波特五力分析
  • 主要相关人员和采购标准
  • 监管状态
  • 影响客户业务的趋势/干扰
  • 专利分析
  • 贸易分析
  • 定价分析
  • 2025-2026 年重要会议与活动
  • 未满足的需求和最终用户的期望
  • 介入肿瘤学市场的最终用户期望
  • 生态系统
  • 案例研究
  • 供应链分析
  • 邻近市场分析
  • 介入肿瘤学市场、投资和资金筹措情景，2020 年至 2023 年
  • 生成式人工智慧对介入性肿瘤学市场的影响

6. 介入性肿瘤学市场（依设备和耗材划分）

  • 介绍
  • 栓塞装置
  • 消融设备
  • 支援的设备

第七章介入肿瘤学市场（依癌症类型）

  • 介绍
  • 肝癌
  • 肾癌
  • 乳癌
  • 肺癌
  • 骨癌
  • 摄护腺癌
  • 其他的

第 8 章 介入性肿瘤学市场（依程序）

  • 介绍
  • 经导管动脉放射栓塞术/选择性内放射治疗 (TARE/SIRT)
  • 经导管动脉化疗栓塞术 (TACE)
  • 经导管动脉栓塞术/BLAND 栓塞术 (TAE)
  • 热感烧蚀
  • 非热感消融

第九章介入肿瘤学市场（依最终用户划分）

  • 介绍
  • 医院
  • 专科门诊
  • 研究和学术机构

第 10 章介入肿瘤学市场（按地区）

  • 介绍
  • 北美洲
    • 北美宏观经济展望
    • 美国
    • 加拿大
  • 欧洲
    • 欧洲宏观经济展望
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 其他的
  • 亚太地区
    • 亚太宏观经济展望
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 其他的
  • 拉丁美洲
    • 拉丁美洲宏观经济展望
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲
    • 宏观经济展望
    • 海湾合作委员会国家
    • 其他的

第十一章 竞争格局

  • 概述
  • 主要参与企业的策略/优势，2021-2024 年
  • 2019 至 2023 年收益分析
  • 2023 年市场占有率分析
  • 公司估值矩阵：主要参与企业，2023 年
  • 公司估值矩阵：Start-Ups/中小企业，2023 年
  • 估值及财务指标
  • 品牌比较
  • 竞争场景

第十二章 公司简介

  • 主要参与企业
    • SIEMENS HEALTHINEERS AG（VARIAN MEDICAL SYSTEMS, INC）
    • BOSTON SCIENTIFIC CORPORATION
    • MEDTRONIC
    • TERUMO CORPORATION
    • MERIT MEDICAL SYSTEMS
    • JOHNSON & JOHNSON MEDTECH（ETHICON）
    • TELEFLEX INCORPORATED
    • ANGIODYNAMICS
    • STRYKER
    • IMBIOTECHNOLOGIES LTD.
    • COOK
    • ICECURE MEDICAL
    • MEDWAVES, INC.
    • PROFOUND MEDICAL
    • RF MEDICAL CO., LTD.
    • MINIMAX MEDICAL LIMITED
    • ABK BIOMEDICAL INC.
    • OLYMPUS CORPORATION
    • SURGNOVA
    • STARMED AMERICA
  • 其他公司
    • SIRTEX SIR-SPHERES PTY LTD.
    • GUERBET
    • ACCURAY INCORPORATED
    • EMBOLX, INC.
    • SONABLATE CORP.

第十三章 附录

Product Code: MD 6975

The interventional oncology market is projected to reach USD 4.24 billion by 2029 from USD 2.75 billion in 2024, at a CAGR of 9.0% during the forecast period. Interventional oncology, has seen significant growth over the past decade. Progress in minimally invasive techniques and an increase in cancer prevalence rates have contributed significantly to this boom. Initially, the market for interventional oncology was underdeveloped owing to the long-standing use of traditional surgical approaches for cancer; however, growing evidence of safety and efficacy from interventional treatments like TACE, TARE, and thermal ablation sparked interest in using these treatments. These techniques have many advantages, such as shorter recovery times, fewer complications, and better overall patient outcomes compared to conventional surgery. The increasing demand for effective treatments for inoperable tumors, especially liver, lung, and kidney cancers, has driven the growth of the market.

Scope of the Report
Years Considered for the Study2024-2029
Base Year2023
Forecast Period2024-2029
Units ConsideredValue (USD)
SegmentsDevices & Consumables, Cancer Type, Procedure, End User and Region
Regions coveredNorth America, Europe, APAC, LATAM, and MEA (GCC Countries, RoMEA)

"By devices & consumables, embolization devices segment is expected to have the largest market share in the interventional oncology market."

Based on devices & consumables, the market share of embolization devices in the interventional oncology sector is highest, as these are crucial tools in minimally invasive cancer treatments that provide an overwhelming advantage over conventional surgical methods. These devices act by reducing or cutting off the blood flow to the tumor, thus starving the tumor of the oxygen and nutrients needed for growth. The growing trend of embolization procedures, TACE, and radioembolization, which is also called selective internal radiation therapy, can be attributed to their proven success in the treatment of inoperable cancers, especially liver cancer, which remains a significant concern in interventional oncology. Improvements in embolic agents, including drug-eluting beads and radioactive microspheres, have improved accuracy and therapeutic outcomes and are therefore becoming more popular. Such factors as the increased global incidence of cancer, increased awareness of non-invasive treatment options, and shift towards outpatient care models further contribute to the growing use of such devices.

"By cancer type, liver cancer segment is expected to have the largest market share in the interventional oncology market."

Based on cancer type, liver cancer is the biggest market share in the interventional oncology segment, primarily due to its increasing global incidence, high mortality rate, and the urgent need for effective, minimally invasive treatment solutions. Hepatocellular carcinoma, the most common form of liver cancer, is closely associated with risk factors such as chronic hepatitis B and C infections, excessive alcohol use, and the growing prevalence of non-alcoholic fatty liver disease. Targeted treatments such as TACE, TARE, and percutaneous ablation in interventional oncology have been very effective in the treatment of unresectable liver cancers. These interventions provide localized tumor control, reduced systemic toxicity, and improved survival outcomes compared to traditional chemotherapy.

"By procedure, transcatheter arterial radioembolization (TARE) or selective internal radiation therapy (SIRT) segment is expected to have the largest market share in the interventional oncology market."

Based on procedure, transcatheter arterial radioembolization (TARE), also referred to as selective internal radiation therapy (SIRT), holds the largest market share in the interventional oncology sector due to its demonstrated efficacy in managing both primary and secondary liver cancers, which account for a significant portion of cancer-related mortalities worldwide. This procedure involves injecting microspheres that are infused with radioactive isotopes, most commonly Yttrium-90, directly into the hepatic artery that feeds the tumor. TARE is effective in killing tumor cells with minimal systemic exposure and reduced damage to healthy surrounding tissues by delivering localized radiation. It is becoming increasingly popular because of a superior safety profile, enhanced tolerability, and fewer adverse effects than conventional chemotherapy and external beam radiation therapy. In addition, TARE is particularly useful in patients with unresectable hepatocellular carcinoma and liver metastases from colorectal cancer, in whom alternative treatments are less effective or unavailable.

"By end user, hospitals segment is expected to have the largest market share in the interventional oncology market."

Based on end user, transcatheter arterial radioembolization (TARE), also referred to as selective internal radiation therapy (SIRT), holds the largest market share in the interventional oncology sector due to its demonstrated efficacy in managing both primary and secondary liver cancers, which account for a significant portion of cancer-related mortalities worldwide. This procedure involves injecting microspheres that are infused with radioactive isotopes, most commonly Yttrium-90, directly into the hepatic artery that feeds the tumor. TARE is effective in killing tumor cells with minimal systemic exposure and reduced damage to healthy surrounding tissues by delivering localized radiation. It is becoming increasingly popular because of a superior safety profile, enhanced tolerability, and fewer adverse effects than conventional chemotherapy and external beam radiation therapy. In addition, TARE is particularly useful in patients with unresectable hepatocellular carcinoma and liver metastases from colorectal cancer, in whom alternative treatments are less effective or unavailable.

"By region, North America region is expected to have the largest market share in the interventional oncology market."

The market share of interventional oncology is dominated by hospitals because of their wide infrastructure, latest technology, and multidisciplinary expertise necessary to perform advanced interventional procedures. Techniques such as TACE, TARE, and tumor ablation are highly specialized and minimally invasive and require access to sophisticated imaging systems, catheterization laboratories, and experienced interventional radiologists. Tertiary care centers and dedicated cancer hospitals have more of such facilities, so these are ideally placed as the first option for interventional oncology treatment. Additionally, a hospital would offer complete treatment; it offers diagnosis, treatment, post-treatment care, and follow-up. This helps in attracting the wide patient spectrum looking for one-stop solutions to treat cancer.

A breakdown of the primary participants (supply-side) for the interventional oncology market referred to for this report is provided below:

  • By Company Type: Tier 1-35%, Tier 2-40%, and Tier 3-25%
  • By Designation: C-level-20%, Director Level-35%, and Others-45%
  • By Region: North America-27%, Europe-25%, Asia Pacific-30%, Latin America- 8%, Middle East & Africa-10% .

Prominent players in the interventional oncology market are are Siemens Healthineers AG (Varian) (US), Medtronic (Ireland), Boston Scientific Corporation (US), Terumo Corporation (Japan), Merit Medical Systems (US), Johnson & Johnson MedTech (Ethicon) (US), Stryker (US), Teleflex Incorporated (US), AngioDynamics (US), Cook (US), Icecure Medical (Israel), Olympus Corporation (Japan), Imbiotechnologies Ltd (Canada), Medwaves Inc (US), Minimax Medical Limited (China), ABK Biomedical Inc (Canada), RF Medical Co., Ltd (South Korea), Profound Medical (Canada), Surgnova (China), STARmed America (US), Sirtex SIR-Spheres Pty Ltd (US), Accuray Incorporated (US), Guerbet (France), Embolx, Inc (Canada) and Sonablate Corp (US).

Research Coverage:

The report analyzes the interventional oncology market and aims at estimating the market size and future growth potential of this market based on various segments such as devices & consumables, cancer type, procedure, end user and region. The report also includes a competitive analysis of the key players in this market along with their company profiles, service offerings, recent developments, and key market strategies.

Reasons to Buy the Report

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall interventional oncology market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.

This report provides insights into the following pointers:

  • Analysis of key drivers (Rising patient preference for minimally invasive procedure, expansion of cancer patient population, increasing public-private funding and government support for interventional oncology, technological advancements in interventional oncology), restraints (High cost of interventional oncology, unfavorable regulations), opportunities (emerging economies offer high growth potential), challenges (dearth of well-trained and skilled radiologist and oncologist, strong market positioning of alternative therapies)
  • ZMarket Penetration: It includes extensive information on products offered by the major players in the global the interventional oncology market. The report includes various segments in offering, application, end user and region.
  • Product Enhancement/Innovation: Comprehensive details about new product launches and anticipated trends in the global interventional oncology market.
  • Market Development: Thorough knowledge and analysis of the profitable rising markets by offering, application, end user and region.
  • Market Diversification: Comprehensive information about newly launched products, expanding markets, current advancements, and investments in the global the interventional oncology market.
  • Competitive Assessment: Thorough evaluation of the market shares, growth plans, offerings of products, and capacities of the major competitors in the global interventional oncology market.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION & SCOPE
    • 1.2.1 INCLUSIONS & EXCLUSIONS
    • 1.2.2 MARKETS COVERED
    • 1.2.3 YEARS CONSIDERED
    • 1.2.4 CURRENCY CONSIDERED
  • 1.3 STAKEHOLDERS
  • 1.4 LIMITATIONS
  • 1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • 2.1.1 SECONDARY DATA
      • 2.1.1.1 Key data from secondary sources
    • 2.1.2 PRIMARY DATA
      • 2.1.2.1 Key data from primary sources
      • 2.1.2.2 Key industry insights
  • 2.2 MARKET SIZE ESTIMATION
  • 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
  • 2.4 MARKET SHARE ESTIMATION
  • 2.5 STUDY ASSUMPTIONS
  • 2.6 RESEARCH LIMITATIONS
    • 2.6.1 METHODOLOGY-RELATED LIMITATIONS
  • 2.7 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

  • 4.1 ATTRACTIVE OPPORTUNITIES FOR PLAYERS IN INTERVENTIONAL ONCOLOGY MARKET
  • 4.2 ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES AND COUNTRY, 2023
  • 4.3 INTERVENTIONAL ONCOLOGY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
  • 4.4 INTERVENTIONAL ONCOLOGY MARKET, BY REGION, 2024-2029
  • 4.5 INTERVENTIONAL ONCOLOGY MARKET: DEVELOPED VS. EMERGING MARKETS

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • 5.2.1 DRIVERS
      • 5.2.1.1 Rising preference for minimally invasive procedures
      • 5.2.1.2 Growing prevalence of cancer
      • 5.2.1.3 Increasing public-private funding and government support for interventional oncology
      • 5.2.1.4 Technological advancements in interventional oncology
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 High cost of interventional oncology
      • 5.2.2.2 Unfavorable regulations
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Emerging economies offer high-growth potential
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Dearth of well-trained and skilled radiologists and oncologists
      • 5.2.4.2 Strong market position of alternative therapies
  • 5.3 INDUSTRY TRENDS
    • 5.3.1 INNOVATIONS IN IMAGING AND TREATMENT TECHNOLOGIES
    • 5.3.2 INCREASING ADOPTION OF MINIMALLY INVASIVE PROCEDURES
  • 5.4 VALUE CHAIN ANALYSIS
  • 5.5 TECHNOLOGY ANALYSIS
    • 5.5.1 KEY TECHNOLOGIES
      • 5.5.1.1 Ablation technologies
      • 5.5.1.2 Embolization technologies
    • 5.5.2 COMPLEMENTARY TECHNOLOGY
      • 5.5.2.1 Laparoscopy
      • 5.5.2.2 Diagnostic imaging
    • 5.5.3 ADJACENT TECHNOLOGY
      • 5.5.3.1 Radiation therapy systems
      • 5.5.3.2 Chemotherapy
  • 5.6 PORTER'S FIVE FORCES ANALYSIS
    • 5.6.1 THREAT OF NEW ENTRANTS
    • 5.6.2 THREAT OF SUBSTITUTES
    • 5.6.3 BARGAINING POWER OF SUPPLIERS
    • 5.6.4 BARGAINING POWER OF BUYERS
    • 5.6.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.7 KEY STAKEHOLDERS AND BUYING CRITERIA
    • 5.7.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • 5.7.2 BUYING CRITERIA
  • 5.8 REGULATORY LANDSCAPE
    • 5.8.1 KEY REGULATORY BODIES AND GOVERNMENT AGENCIES
    • 5.8.2 KEY REGULATORY GUIDELINES
      • 5.8.2.1 US
      • 5.8.2.2 Canada
      • 5.8.2.3 Europe
      • 5.8.2.4 Asia Pacific
        • 5.8.2.4.1 Japan
        • 5.8.2.4.2 China
        • 5.8.2.4.3 India
      • 5.8.2.5 Brazil
  • 5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
  • 5.10 PATENT ANALYSIS
    • 5.10.1 PATENT PUBLICATION TRENDS FOR INTERVENTIONAL ONCOLOGY, JANUARY 2014-DECEMBER 2024
  • 5.11 TRADE ANALYSIS
  • 5.12 PRICING ANALYSIS
    • 5.12.1 AVERAGE SELLING PRICE OF INTERVENTIONAL ONCOLOGY DEVICES, BY KEY PLAYER, 2023
    • 5.12.2 AVERAGE SELLING PRICE OF INTERVENTIONAL ONCOLOGY DEVICES, BY KEY PLAYER, 2023 (USD)
    • 5.12.3 AVERAGE SELLING PRICE TREND OF INTERVENTIONAL ONCOLOGY DEVICES, BY REGION, 2021-2023
  • 5.13 KEY CONFERENCES AND EVENTS, 2025-2026
  • 5.14 UNMET NEEDS AND END USER EXPECTATIONS
    • 5.14.1 UNMET NEEDS
  • 5.15 END USER EXPECTATIONS IN INTERVENTIONAL ONCOLOGY MARKET
  • 5.16 ECOSYSTEM
  • 5.17 CASE STUDIES
  • 5.18 SUPPLY CHAIN ANALYSIS
  • 5.19 ADJACENT MARKET ANALYSIS
  • 5.20 INTERVENTIONAL ONCOLOGY MARKET, INVESTMENT AND FUNDING SCENARIO, 2020-2023
  • 5.21 IMPACT OF GENERATIVE AI ON INTERVENTIONAL ONCOLOGY MARKET

6 INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES

  • 6.1 INTRODUCTION
  • 6.2 EMBOLIZATION DEVICES
    • 6.2.1 RADIOEMBOLIC AGENTS
      • 6.2.1.1 Precision-targeted therapy for challenging liver cancers to boost market
    • 6.2.2 NON-RADIOACTIVE EMBOLIC AGENTS
      • 6.2.2.1 Non-radiation emitting agents to propel market
      • 6.2.2.2 Microspheres
        • 6.2.2.2.1 Surge in prevalence of hepatocellular carcinoma to fuel growth
      • 6.2.2.3 Coated beads
        • 6.2.2.3.1 Specialized polymer coatings with enhanced ability to bind, absorb, and release chemotherapeutic agents to drive market
      • 6.2.2.4 Microparticles
        • 6.2.2.4.1 Use in various cancer applications to drive growth
  • 6.3 ABLATION DEVICES
    • 6.3.1 RADIOFREQUENCY (RF) ABLATION DEVICES
      • 6.3.1.1 Effective treatment of small or difficult-to-reach tumors to propel market growth
    • 6.3.2 MICROWAVE ABLATION DEVICES
      • 6.3.2.1 Simultaneous treatment of multiple lesions to drive market growth
    • 6.3.3 CRYOABLATION DEVICES
      • 6.3.3.1 Least painful and higher patient compatibility to drive market
    • 6.3.4 OTHER ABLATION DEVICES
  • 6.4 SUPPORT DEVICES
    • 6.4.1 MICROCATHETERS
      • 6.4.1.1 Precise delivery of therapeutic agents to tumors to boost market
    • 6.4.2 GUIDEWIRES
      • 6.4.2.1 Advancements in guidewire construction and launch of new and advanced products to propel market
    • 6.4.3 OTHER SUPPORT DEVICES

7 INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE

  • 7.1 INTRODUCTION
  • 7.2 LIVER CANCER
    • 7.2.1 INCREASING DISEASE PREVALENCE AND RISING RESEARCH ACTIVITIES TO DRIVE MARKET GROWTH
  • 7.3 KIDNEY CANCER
    • 7.3.1 FIRST-LINE THERAPY PRESERVING MORE KIDNEY TISSUE THAN SURGERY TO BOOST MARKET
  • 7.4 BREAST CANCER
    • 7.4.1 HIGH PRECISION, BETTER COSMETIC OUTCOMES, COST-EFFECTIVENESS, AND GREATER PATIENT COMFORT TO PROPEL MARKET
  • 7.5 LUNG CANCER
    • 7.5.1 INCREASING NUMBER OF CANCER CASES TO DRIVE DEMAND
  • 7.6 BONE CANCER
    • 7.6.1 DIRECT ELIMINATION OF TUMORS AND PAIN RELIEF TO FUEL MARKET
  • 7.7 PROSTATE CANCER
    • 7.7.1 RISING INCIDENCE OF PROSTATE CANCER AND GROWING ADOPTION OF METAL-BASED FIDUCIAL MARKERS TO CONTRIBUTE TO MARKET GROWTH
  • 7.8 OTHER CANCER TYPES

8 INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE

  • 8.1 INTRODUCTION
  • 8.2 TRANSCATHETER ARTERIAL RADIOEMBOLIZATION/SELECTIVE INTERNAL RADIATION THERAPY (TARE/SIRT)
    • 8.2.1 GREATER CLINICAL EFFICACY TO DRIVE MARKET GROWTH
  • 8.3 TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION (TACE)
    • 8.3.1 ABILITY TO TREAT SMALL AND LARGE-SIZED TUMORS TO DRIVE DEMAND
  • 8.4 TRANSCATHETER ARTERIAL EMBOLIZATION/BLAND EMBOLIZATION (TAE)
    • 8.4.1 INCREASING CLINICAL EVIDENCE IN FAVOR OF TARE AND TACE TO RESTRAIN MARKET GROWTH
  • 8.5 THERMAL TUMOR ABLATION
    • 8.5.1 GROWING CLINICAL EVIDENCE PROVING EFFICACY OF TREATMENT OF VARIOUS TYPES OF CANCERS TO DRIVE MARKET GROWTH
  • 8.6 NON-THERMAL TUMOR ABLATION
    • 8.6.1 POTENTIAL ALTERNATIVE TO THERMAL TUMOR ABLATION TO BOOST MARKET

9 INTERVENTIONAL ONCOLOGY MARKET, BY END USER

  • 9.1 INTRODUCTION
  • 9.2 HOSPITALS
    • 9.2.1 INCREASING NUMBER OF SURGERIES IN IN-PATIENT SETTINGS TO SUPPORT MARKET GROWTH
  • 9.3 SPECIALTY CLINICS
    • 9.3.1 INCREASING NUMBER OF CANCER CENTERS TO DRIVE MARKET GROWTH
  • 9.4 RESEARCH & ACADEMIC INSTITUTES
    • 9.4.1 COLLABORATIONS AMONG DEVICE MANUFACTURERS AND SUPPLIERS TO FUEL MARKET

10 INTERVENTIONAL ONCOLOGY MARKET, BY REGION

  • 10.1 INTRODUCTION
  • 10.2 NORTH AMERICA
    • 10.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
    • 10.2.2 US
      • 10.2.2.1 Rising cancer cases and preference for ablation procedures to boost market
    • 10.2.3 CANADA
      • 10.2.3.1 Significant rise in cancer cases to drive market growth
  • 10.3 EUROPE
    • 10.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
    • 10.3.2 GERMANY
      • 10.3.2.1 Increase in incidence of cancer and rising geriatric population to fuel market
    • 10.3.3 UK
      • 10.3.3.1 Increasing awareness and support for cancer-related activities to drive market
    • 10.3.4 FRANCE
      • 10.3.4.1 Growing geriatric population to support market growth
    • 10.3.5 SPAIN
      • 10.3.5.1 Increasing government funding for research to support market growth
    • 10.3.6 ITALY
      • 10.3.6.1 Growing awareness about cancer and treatment options to support market growth
    • 10.3.7 REST OF EUROPE
  • 10.4 ASIA PACIFIC
    • 10.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
    • 10.4.2 JAPAN
      • 10.4.2.1 Rising geriatric population and universal healthcare reimbursement to drive market
    • 10.4.3 CHINA
      • 10.4.3.1 Increasing incidence of cancer to drive market
    • 10.4.4 INDIA
      • 10.4.4.1 Improving research capabilities and expansion of key players to drive market growth
    • 10.4.5 AUSTRALIA
      • 10.4.5.1 Rising investments in research and awareness campaigns to support market growth
    • 10.4.6 SOUTH KOREA
      • 10.4.6.1 Rising R&D and promising clinical trials to positively impact market growth
    • 10.4.7 REST OF ASIA PACIFIC
  • 10.5 LATIN AMERICA
    • 10.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
    • 10.5.2 BRAZIL
      • 10.5.2.1 Rising incidence of cancer and improving healthcare infrastructure to fuel market
    • 10.5.3 MEXICO
      • 10.5.3.1 Increasing awareness campaigns and rising incidence of cancer to drive market growth
    • 10.5.4 REST OF LATIN AMERICA
  • 10.6 MIDDLE EAST & AFRICA
    • 10.6.1 MACROECONOMIC OUTLOOK
    • 10.6.2 GCC COUNTRIES
      • 10.6.2.1 Broader healthcare modernization initiatives in interventional oncology to drive market
    • 10.6.3 REST OF MIDDLE EAST & AFRICA

11 COMPETITIVE LANDSCAPE

  • 11.1 OVERVIEW
  • 11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2021-2024
  • 11.3 REVENUE ANALYSIS, 2019-2023
  • 11.4 MARKET SHARE ANALYSIS, 2023
  • 11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
    • 11.5.1 STARS
    • 11.5.2 EMERGING LEADERS
    • 11.5.3 PERVASIVE PLAYERS
    • 11.5.4 PARTICIPANTS
    • 11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
      • 11.5.5.1 Company footprint
      • 11.5.5.2 Region footprint
      • 11.5.5.3 Devices & Consumables footprint
      • 11.5.5.4 Cancer type footprint
      • 11.5.5.5 Procedure footprint
      • 11.5.5.6 End user footprint
  • 11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
    • 11.6.1 PROGRESSIVE COMPANIES
    • 11.6.2 DYNAMIC COMPANIES
    • 11.6.3 STARTING BLOCKS
    • 11.6.4 RESPONSIVE COMPANIES
    • 11.6.5 COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES, 2023
      • 11.6.5.1 Detailed list of key startups/SMES, 2023
      • 11.6.5.2 Competitive benchmarking of key startups/SMEs
  • 11.7 VALUATION & FINANCIAL METRICS
    • 11.7.1 FINANCIAL METRICS
    • 11.7.2 COMPANY VALUATION
  • 11.8 BRAND COMPARISON
  • 11.9 COMPETITIVE SCENARIO
    • 11.9.1 PRODUCT & SERVICE LAUNCHES AND APPROVALS
    • 11.9.2 DEALS
    • 11.9.3 EXPANSIONS

12 COMPANY PROFILES

  • 12.1 KEY PLAYERS
    • 12.1.1 SIEMENS HEALTHINEERS AG (VARIAN MEDICAL SYSTEMS, INC)
      • 12.1.1.1 Business overview
      • 12.1.1.2 Products/Solutions/Services offered
      • 12.1.1.3 Recent developments
        • 12.1.1.3.1 Product launches & approvals
        • 12.1.1.3.2 Deals
      • 12.1.1.4 MnM view
        • 12.1.1.4.1 Right to win
        • 12.1.1.4.2 Strategic choices
        • 12.1.1.4.3 Weaknesses and competitive threats
    • 12.1.2 BOSTON SCIENTIFIC CORPORATION
      • 12.1.2.1 Business overview
      • 12.1.2.2 Products/Solutions/Services offered
      • 12.1.2.3 Recent developments
        • 12.1.2.3.1 Product launches & approvals
        • 12.1.2.3.2 Deals
      • 12.1.2.4 MnM view
        • 12.1.2.4.1 Right to win
        • 12.1.2.4.2 Strategic choices
        • 12.1.2.4.3 Weaknesses and competitive threats
    • 12.1.3 MEDTRONIC
      • 12.1.3.1 Business overview
      • 12.1.3.2 Products/Solutions/Services offered
      • 12.1.3.3 MnM view
        • 12.1.3.3.1 Right to win
        • 12.1.3.3.2 Strategic choices
        • 12.1.3.3.3 Weaknesses and competitive threats
    • 12.1.4 TERUMO CORPORATION
      • 12.1.4.1 Business overview
      • 12.1.4.2 Products/Solutions/Services offered
      • 12.1.4.3 Recent developments
        • 12.1.4.3.1 Expansions
      • 12.1.4.4 MnM view
        • 12.1.4.4.1 Right to win
        • 12.1.4.4.2 Strategic choices
        • 12.1.4.4.3 Weaknesses and competitive threats
    • 12.1.5 MERIT MEDICAL SYSTEMS
      • 12.1.5.1 Business overview
      • 12.1.5.2 Products/Solutions/Services offered
      • 12.1.5.3 Recent developments
        • 12.1.5.3.1 Expansions
      • 12.1.5.4 MnM view
        • 12.1.5.4.1 Right to win
        • 12.1.5.4.2 Strategic choices
        • 12.1.5.4.3 Weaknesses and competitive threats
    • 12.1.6 JOHNSON & JOHNSON MEDTECH (ETHICON)
      • 12.1.6.1 Business overview
      • 12.1.6.2 Products/Solutions/Services offered
    • 12.1.7 TELEFLEX INCORPORATED
      • 12.1.7.1 Business overview
      • 12.1.7.2 Products/Solutions/Services offered
    • 12.1.8 ANGIODYNAMICS
      • 12.1.8.1 Business overview
      • 12.1.8.2 Products/Solutions/Services offered
      • 12.1.8.3 Recent developments
        • 12.1.8.3.1 Product launches & approvals
    • 12.1.9 STRYKER
      • 12.1.9.1 Business overview
      • 12.1.9.2 Products/Solutions/Services offered
    • 12.1.10 IMBIOTECHNOLOGIES LTD.
      • 12.1.10.1 Business overview
      • 12.1.10.2 Products/Solutions/Services offered
    • 12.1.11 COOK
      • 12.1.11.1 Business overview
      • 12.1.11.2 Products/Solutions/Services offered
    • 12.1.12 ICECURE MEDICAL
      • 12.1.12.1 Business overview
      • 12.1.12.2 Products/Solutions/Services offered
      • 12.1.12.3 Recent developments
        • 12.1.12.3.1 Product approvals
        • 12.1.12.3.2 Deals
    • 12.1.13 MEDWAVES, INC.
      • 12.1.13.1 Business overview
      • 12.1.13.2 Products/Solutions/Services offered
    • 12.1.14 PROFOUND MEDICAL
      • 12.1.14.1 Business overview
      • 12.1.14.2 Products/Solutions/Services offered
    • 12.1.15 RF MEDICAL CO., LTD.
      • 12.1.15.1 Business overview
      • 12.1.15.2 Products/Solutions/Services offered
    • 12.1.16 MINIMAX MEDICAL LIMITED
      • 12.1.16.1 Business overview
      • 12.1.16.2 Products/Solutions/Services offered
    • 12.1.17 ABK BIOMEDICAL INC.
      • 12.1.17.1 Business overview
      • 12.1.17.2 Products/Solutions/Services offered
    • 12.1.18 OLYMPUS CORPORATION
      • 12.1.18.1 Business overview
      • 12.1.18.2 Products/Solutions/Services offered
    • 12.1.19 SURGNOVA
      • 12.1.19.1 Business overview
      • 12.1.19.2 Products/Solutions/Services offered
    • 12.1.20 STARMED AMERICA
      • 12.1.20.1 Business overview
      • 12.1.20.2 Products/Solutions/Services offered
  • 12.2 OTHER PLAYERS
    • 12.2.1 SIRTEX SIR-SPHERES PTY LTD.
    • 12.2.2 GUERBET
    • 12.2.3 ACCURAY INCORPORATED
    • 12.2.4 EMBOLX, INC.
    • 12.2.5 SONABLATE CORP.

13 APPENDIX

  • 13.1 DISCUSSION GUIDE
  • 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 13.3 CUSTOMIZATION OPTIONS
  • 13.4 RELATED REPORTS
  • 13.5 AUTHOR DETAILS

List of Tables

  • TABLE 1 STANDARD CURRENCY CONVERSION RATES
  • TABLE 2 RISK ASSESSMENT: INTERVENTIONAL ONCOLOGY MARKET
  • TABLE 3 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF EMBOLIZATION DEVICES, ABLATION DEVICES, AND SUPPORT DEVICES
  • TABLE 4 KEY BUYING CRITERIA FOR EMBOLIZATION DEVICES, ABLATION DEVICES, AND SUPPORT DEVICES
  • TABLE 5 NORTH AMERICA: LIST OF REGULATORY BODIES AND GOVERNMENT AGENCIES
  • TABLE 6 EUROPE: LIST OF REGULATORY BODIES AND GOVERNMENT AGENCIES
  • TABLE 7 ASIA PACIFIC: LIST OF REGULATORY BODIES AND GOVERNMENT AGENCIES
  • TABLE 8 LATIN AMERICA: LIST OF REGULATORY BODIES AND GOVERNMENT AGENCIES
  • TABLE 9 MIDDLE EAST & AFRICA: LIST OF REGULATORY BODIES AND GOVERNMENT AGENCIES
  • TABLE 10 US FDA: MEDICAL DEVICE CLASSIFICATION
  • TABLE 11 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS
  • TABLE 12 CANADA: MEDICAL DEVICE REGULATORY APPROVAL PROCESS
  • TABLE 13 JAPAN: PMDA CLASSIFICATION OF ABLATION DEVICES
  • TABLE 14 JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PHARMACEUTICAL AND MEDICAL DEVICE AGENCY (PMDA)
  • TABLE 15 CHINA: CLASSIFICATION OF MEDICAL DEVICES
  • TABLE 16 INDIA: CDSCO CLASSIFICATION OF ABLATION DEVICES
  • TABLE 17 LIST OF PATENTS IN INTERVENTIONAL ONCOLOGY MARKET, 2021-2024
  • TABLE 18 IMPORT DATA FOR INTERVENTIONAL ONCOLOGY (HS CODE 9018), BY COUNTRY, 2019-2023 (USD THOUSAND)
  • TABLE 19 EXPORT DATA FOR INTERVENTIONAL ONCOLOGY (HS CODE 9018), BY COUNTRY, 2019-2023 (USD THOUSAND)
  • TABLE 20 AVERAGE SELLING PRICE OF INTERVENTIONAL ONCOLOGY DEVICES, BY KEY PLAYER, 2023 (USD)
  • TABLE 21 AVERAGE SELLING PRICE TREND OF INTERVENTIONAL ONCOLOGY DEVICES, BY REGION, 2021-2023
  • TABLE 22 INTERVENTIONAL ONCOLOGY MARKET: KEY CONFERENCES & EVENTS, 2025-2026
  • TABLE 23 END USER EXPECTATIONS FOR EMBOLIZATION DEVICES, ABLATION DEVICES, AND SUPPORT DEVICES
  • TABLE 24 INTERVENTIONAL ONCOLOGY MARKET: ECOSYSTEM ANALYSIS
  • TABLE 25 TREATMENT OF HEPATOCELLULAR CARCINOMA WITH ARTERIOPORTAL SHUNTING USING BALLOON-ASSISTED TRANSARTERIAL YTTRIUM-90 RADIATION SEGMENTECTOMY
  • TABLE 26 RADIOFREQUENCY ABLATION ANALYSIS CASE STUDY
  • TABLE 27 UPPER POLE ANGIOMYOLIPOMA (AML) EMBOLIZATION
  • TABLE 28 INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2019-2023 (USD MILLION)
  • TABLE 29 INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2024-2029 (USD MILLION)
  • TABLE 30 INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019-2023 (USD MILLION)
  • TABLE 31 INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 32 INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY REGION, 2019-2023 (USD MILLION)
  • TABLE 33 INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY REGION, 2024-2029 (USD MILLION)
  • TABLE 34 RADIOEMBOLIC AGENTS OFFERED BY MAJOR MARKET PLAYERS
  • TABLE 35 INTERVENTIONAL ONCOLOGY MARKET FOR RADIOEMBOLIC AGENTS, BY REGION, 2019-2023 (USD MILLION)
  • TABLE 36 INTERVENTIONAL ONCOLOGY MARKET FOR RADIOEMBOLIC AGENTS, BY REGION, 2024-2029 (USD MILLION)
  • TABLE 37 NON-RADIOACTIVE EMBOLIC AGENTS OFFERED BY MAJOR MARKET PLAYERS
  • TABLE 38 INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE EMBOLIC AGENTS, BY TYPE, 2019-2023 (USD MILLION)
  • TABLE 39 INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE EMBOLIC AGENTS, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 40 INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE EMBOLIC AGENTS, BY REGION, 2019-2023 (USD MILLION)
  • TABLE 41 INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE EMBOLIC AGENTS, BY REGION, 2024-2029 (USD MILLION)
  • TABLE 42 INTERVENTIONAL ONCOLOGY MARKET FOR MICROSPHERES, BY REGION, 2019-2023 (USD MILLION)
  • TABLE 43 INTERVENTIONAL ONCOLOGY MARKET FOR MICROSPHERES, BY REGION, 2024-2029 (USD MILLION)
  • TABLE 44 INTERVENTIONAL ONCOLOGY MARKET FOR COATED BEADS, BY REGION, 2019-2023 (USD MILLION)
  • TABLE 45 INTERVENTIONAL ONCOLOGY MARKET FOR COATED BEADS, BY REGION, 2024-2029 (USD MILLION)
  • TABLE 46 MAJOR BRANDS OF MICROCARRIERS
  • TABLE 47 INTERVENTIONAL ONCOLOGY MARKET FOR MICROPARTICLES, BY REGION, 2019-2023 (USD MILLION)
  • TABLE 48 INTERVENTIONAL ONCOLOGY MARKET FOR MICROPARTICLES, BY REGION, 2024-2029 (USD MILLION)
  • TABLE 49 INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019-2023 (USD MILLION)
  • TABLE 50 INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 51 INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY REGION, 2019-2023 (USD MILLION)
  • TABLE 52 INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY REGION, 2024-2029 (USD MILLION)
  • TABLE 53 RADIOFREQUENCY ABLATION DEVICES OFFERED BY MAJOR MARKET PLAYERS
  • TABLE 54 INTERVENTIONAL ONCOLOGY MARKET FOR RADIOFREQUENCY ABLATION DEVICES, BY REGION, 2019-2023 (USD MILLION)
  • TABLE 55 INTERVENTIONAL ONCOLOGY MARKET FOR RADIOFREQUENCY ABLATION DEVICES, BY REGION, 2024-2029 (USD MILLION)
  • TABLE 56 RADIOFREQUENCY ABLATION SYSTEMS, BY REGION, 2023-2029 (THOUSAND UNITS)
  • TABLE 57 INTERVENTIONAL ONCOLOGY MARKET FOR MICROWAVE ABLATION DEVICES, BY REGION, 2019-2023 (USD MILLION)
  • TABLE 58 INTERVENTIONAL ONCOLOGY MARKET FOR MICROWAVE ABLATION DEVICES, BY REGION, 2024-2029 (USD MILLION)
  • TABLE 59 MICROWAVE ABLATION SYSTEMS, BY REGION, 2023-2029 (THOUSAND UNITS)
  • TABLE 60 INTERVENTIONAL ONCOLOGY MARKET FOR CRYOABLATION DEVICES, BY REGION, 2019-2023 (USD MILLION)
  • TABLE 61 INTERVENTIONAL ONCOLOGY MARKET FOR CRYOABLATION DEVICES, BY REGION, 2024-2029 (USD MILLION)
  • TABLE 62 INTERVENTIONAL ONCOLOGY MARKET FOR OTHER ABLATION DEVICES, BY REGION, 2019-2023 (USD MILLION)
  • TABLE 63 INTERVENTIONAL ONCOLOGY MARKET FOR OTHER ABLATION DEVICES, BY REGION, 2024-2029 (USD MILLION)
  • TABLE 64 INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019-2023 (USD MILLION)
  • TABLE 65 INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 66 INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY REGION, 2019-2023 (USD MILLION)
  • TABLE 67 INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY REGION, 2024-2029 (USD MILLION)
  • TABLE 68 INTERVENTIONAL ONCOLOGY MARKET FOR MICROCATHETERS, BY REGION, 2019-2023 (USD MILLION)
  • TABLE 69 INTERVENTIONAL ONCOLOGY MARKET FOR MICROCATHETERS, BY REGION, 2024-2029 (USD MILLION)
  • TABLE 70 INTERVENTIONAL ONCOLOGY MARKET FOR GUIDEWIRES, BY REGION, 2019-2023 (USD MILLION)
  • TABLE 71 INTERVENTIONAL ONCOLOGY MARKET FOR GUIDEWIRES, BY REGION, 2024-2029 (USD MILLION)
  • TABLE 72 INTERVENTIONAL ONCOLOGY MARKET FOR OTHER SUPPORT DEVICES, BY REGION, 2019-2023 (USD MILLION)
  • TABLE 73 INTERVENTIONAL ONCOLOGY MARKET FOR OTHER SUPPORT DEVICES, BY REGION, 2024-2029 (USD MILLION)
  • TABLE 74 INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2019-2023 (USD MILLION)
  • TABLE 75 INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2024-2029 (USD MILLION)
  • TABLE 76 INTERVENTIONAL ONCOLOGY MARKET FOR LIVER CANCER, BY REGION, 2019-2023 (USD MILLION)
  • TABLE 77 INTERVENTIONAL ONCOLOGY MARKET FOR LIVER CANCER, BY REGION, 2024-2029 (USD MILLION)
  • TABLE 78 INTERVENTIONAL ONCOLOGY MARKET FOR KIDNEY CANCER, BY REGION, 2019-2023 (USD MILLION)
  • TABLE 79 INTERVENTIONAL ONCOLOGY MARKET FOR KIDNEY CANCER, BY REGION, 2024-2029 (USD MILLION)
  • TABLE 80 INTERVENTIONAL ONCOLOGY MARKET FOR BREAST CANCER, BY REGION, 2019-2023 (USD MILLION)
  • TABLE 81 INTERVENTIONAL ONCOLOGY MARKET FOR BREAST CANCER, BY REGION, 2024-2029 (USD MILLION)
  • TABLE 82 INTERVENTIONAL ONCOLOGY MARKET FOR LUNG CANCER, BY REGION, 2019-2023 (USD MILLION)
  • TABLE 83 INTERVENTIONAL ONCOLOGY MARKET FOR LUNG CANCER, BY REGION, 2024-2029 (USD MILLION)
  • TABLE 84 INTERVENTIONAL ONCOLOGY MARKET FOR BONE CANCER, BY REGION, 2019-2023 (USD MILLION)
  • TABLE 85 INTERVENTIONAL ONCOLOGY MARKET FOR BONE CANCER, BY REGION, 2024-2029 (USD MILLION)
  • TABLE 86 INTERVENTIONAL ONCOLOGY MARKET FOR PROSTATE CANCER, BY REGION, 2019-2023 (USD MILLION)
  • TABLE 87 INTERVENTIONAL ONCOLOGY MARKET FOR PROSTATE CANCER, BY REGION, 2024-2029 (USD MILLION)
  • TABLE 88 INTERVENTIONAL ONCOLOGY MARKET FOR OTHER CANCER TYPES, BY REGION, 2019-2023 (USD MILLION)
  • TABLE 89 INTERVENTIONAL ONCOLOGY MARKET FOR OTHER CANCER TYPES, BY REGION, 2024-2029 (USD MILLION)
  • TABLE 90 INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2019-2023 (USD MILLION)
  • TABLE 91 INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2024-2029 (USD MILLION)
  • TABLE 92 INTERVENTIONAL ONCOLOGY MARKET FOR TRANSCATHETER ARTERIAL RADIOEMBOLIZATION/SELECTIVE INTERNAL RADIATION THERAPY (TARE/SIRT), BY REGION, 2019-2023 (USD MILLION)
  • TABLE 93 INTERVENTIONAL ONCOLOGY MARKET FOR TRANSCATHETER ARTERIAL RADIOEMBOLIZATION/SELECTIVE INTERNAL RADIATION THERAPY (TARE/SIRT), BY REGION, 2024-2029 (USD MILLION)
  • TABLE 94 INTERVENTIONAL ONCOLOGY MARKET FOR TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION (TACE), BY REGION, 2019-2023 (USD MILLION)
  • TABLE 95 INTERVENTIONAL ONCOLOGY MARKET FOR TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION (TACE), BY REGION, 2024-2029 (USD MILLION)
  • TABLE 96 INTERVENTIONAL ONCOLOGY MARKET FOR TRANSCATHETER ARTERIAL EMBOLIZATION/BLAND EMBOLIZATION (TAE), BY REGION, 2019-2023 (USD MILLION)
  • TABLE 97 INTERVENTIONAL ONCOLOGY MARKET FOR TRANSCATHETER ARTERIAL EMBOLIZATION/BLAND EMBOLIZATION (TAE), BY REGION, 2024-2029 (USD MILLION)
  • TABLE 98 INTERVENTIONAL ONCOLOGY MARKET FOR THERMAL TUMOR ABLATION, BY REGION, 2019-2023 (USD MILLION)
  • TABLE 99 INTERVENTIONAL ONCOLOGY MARKET FOR THERMAL TUMOR ABLATION, BY REGION, 2024-2029 (USD MILLION)
  • TABLE 100 INTERVENTIONAL ONCOLOGY MARKET FOR NON-THERMAL TUMOR ABLATION, BY REGION, 2019-2023 (USD MILLION)
  • TABLE 101 INTERVENTIONAL ONCOLOGY MARKET FOR NON-THERMAL TUMOR ABLATION, BY REGION, 2024-2029 (USD MILLION)
  • TABLE 102 INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2019-2023 (USD MILLION)
  • TABLE 103 INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2024-2029 (USD MILLION)
  • TABLE 104 INTERVENTIONAL ONCOLOGY MARKET FOR HOSPITALS, BY REGION, 2019-2023 (USD MILLION)
  • TABLE 105 INTERVENTIONAL ONCOLOGY MARKET FOR HOSPITALS, BY REGION, 2024-2029 (USD MILLION)
  • TABLE 106 INTERVENTIONAL ONCOLOGY MARKET FOR SPECIALTY CLINICS, BY REGION, 2019-2023 (USD MILLION)
  • TABLE 107 INTERVENTIONAL ONCOLOGY MARKET FOR SPECIALTY CLINICS, BY REGION, 2024-2029 (USD MILLION)
  • TABLE 108 INTERVENTIONAL ONCOLOGY MARKET FOR RESEARCH & ACADEMIC INSTITUTES, BY REGION, 2019-2023 (USD MILLION)
  • TABLE 109 INTERVENTIONAL ONCOLOGY MARKET FOR RESEARCH & ACADEMIC INSTITUTES, BY REGION, 2024-2029 (USD MILLION)
  • TABLE 110 INTERVENTIONAL ONCOLOGY MARKET, BY REGION, 2019-2023 (USD MILLION)
  • TABLE 111 INTERVENTIONAL ONCOLOGY MARKET, BY REGION, 2024-2029 (USD MILLION)
  • TABLE 112 NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY COUNTRY, 2019-2023 (USD MILLION)
  • TABLE 113 NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY COUNTRY, 2024-2029 (USD MILLION)
  • TABLE 114 NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2019-2023 (USD MILLION)
  • TABLE 115 NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2024-2029 (USD MILLION)
  • TABLE 116 NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019-2023 (USD MILLION)
  • TABLE 117 NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 118 NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2019-2023 (USD MILLION)
  • TABLE 119 NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 120 NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019-2023 (USD MILLION)
  • TABLE 121 NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 122 NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019-2023 (USD MILLION)
  • TABLE 123 NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 124 NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2019-2023 (USD MILLION)
  • TABLE 125 NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2024-2029 (USD MILLION)
  • TABLE 126 NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2019-2023 (USD MILLION)
  • TABLE 127 NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2024-2029 (USD MILLION)
  • TABLE 128 NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2019-2023 (USD MILLION)
  • TABLE 129 NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2024-2029 (USD MILLION)
  • TABLE 130 US: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2019-2023 (USD MILLION)
  • TABLE 131 US: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2024-2029 (USD MILLION)
  • TABLE 132 US: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019-2023 (USD MILLION)
  • TABLE 133 US: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 134 US: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2019-2023 (USD MILLION)
  • TABLE 135 US: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 136 US: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019-2023 (USD MILLION)
  • TABLE 137 US: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 138 US: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019-2023 (USD MILLION)
  • TABLE 139 US: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 140 US: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2019-2023 (USD MILLION)
  • TABLE 141 US: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2024-2029 (USD MILLION)
  • TABLE 142 US: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2019-2023 (USD MILLION)
  • TABLE 143 US: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2024-2029 (USD MILLION)
  • TABLE 144 US: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2019-2023 (USD MILLION)
  • TABLE 145 US: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2024-2029 (USD MILLION)
  • TABLE 146 CANADA: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2019-2023 (USD MILLION)
  • TABLE 147 CANADA: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2024-2029 (USD MILLION)
  • TABLE 148 CANADA: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019-2023 (USD MILLION)
  • TABLE 149 CANADA: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 150 CANADA: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2019-2023 (USD MILLION)
  • TABLE 151 CANADA: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 152 CANADA: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019-2023 (USD MILLION)
  • TABLE 153 CANADA: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 154 CANADA: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019-2023 (USD MILLION)
  • TABLE 155 CANADA: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 156 CANADA: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2019-2023 (USD MILLION)
  • TABLE 157 CANADA: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2024-2029 (USD MILLION)
  • TABLE 158 CANADA: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2019-2023 (USD MILLION)
  • TABLE 159 CANADA: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2024-2029 (USD MILLION)
  • TABLE 160 CANADA: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2019-2023 (USD MILLION)
  • TABLE 161 CANADA: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2024-2029 (USD MILLION)
  • TABLE 162 EUROPE: INTERVENTIONAL ONCOLOGY MARKET, BY COUNTRY, 2019-2023 (USD MILLION)
  • TABLE 163 EUROPE: INTERVENTIONAL ONCOLOGY MARKET, BY COUNTRY, 2024-2029 (USD MILLION)
  • TABLE 164 EUROPE: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2019-2023 (USD MILLION)
  • TABLE 165 EUROPE: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2024-2029 (USD MILLION)
  • TABLE 166 EUROPE: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019-2023 (USD MILLION)
  • TABLE 167 EUROPE: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 168 EUROPE: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2019-2023 (USD MILLION)
  • TABLE 169 EUROPE: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 170 EUROPE: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019-2023 (USD MILLION)
  • TABLE 171 EUROPE: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 172 EUROPE: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019-2023 (USD MILLION)
  • TABLE 173 EUROPE: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 174 EUROPE: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2019-2023 (USD MILLION)
  • TABLE 175 EUROPE: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2024-2029 (USD MILLION)
  • TABLE 176 EUROPE: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2019-2023 (USD MILLION)
  • TABLE 177 EUROPE: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2024-2029 (USD MILLION)
  • TABLE 178 EUROPE: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2019-2023 (USD MILLION)
  • TABLE 179 EUROPE: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2024-2029 (USD MILLION)
  • TABLE 180 GERMANY: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2019-2023 (USD MILLION)
  • TABLE 181 GERMANY: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2024-2029 (USD MILLION)
  • TABLE 182 GERMANY: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019-2023 (USD MILLION)
  • TABLE 183 GERMANY: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 184 GERMANY: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2019-2023 (USD MILLION)
  • TABLE 185 GERMANY: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 186 GERMANY: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019-2023 (USD MILLION)
  • TABLE 187 GERMANY: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 188 GERMANY: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019-2023 (USD MILLION)
  • TABLE 189 GERMANY: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 190 GERMANY: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2019-2023 (USD MILLION)
  • TABLE 191 GERMANY: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2024-2029 (USD MILLION)
  • TABLE 192 GERMANY: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2019-2023 (USD MILLION)
  • TABLE 193 GERMANY: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2024-2029 (USD MILLION)
  • TABLE 194 GERMANY: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2019-2023 (USD MILLION)
  • TABLE 195 GERMANY: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2024-2029 (USD MILLION)
  • TABLE 196 UK: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2019-2023 (USD MILLION)
  • TABLE 197 UK: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2024-2029 (USD MILLION)
  • TABLE 198 UK: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019-2023 (USD MILLION)
  • TABLE 199 UK: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 200 UK: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2019-2023 (USD MILLION)
  • TABLE 201 UK: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 202 UK: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019-2023 (USD MILLION)
  • TABLE 203 UK: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 204 UK: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019-2023 (USD MILLION)
  • TABLE 205 UK: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 206 UK: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2019-2023 (USD MILLION)
  • TABLE 207 UK: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2024-2029 (USD MILLION)
  • TABLE 208 UK: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2019-2023 (USD MILLION)
  • TABLE 209 UK: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2024-2029 (USD MILLION)
  • TABLE 210 UK: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2019-2023 (USD MILLION)
  • TABLE 211 UK: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2024-2029 (USD MILLION)
  • TABLE 212 FRANCE: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2019-2023 (USD MILLION)
  • TABLE 213 FRANCE: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2024-2029 (USD MILLION)
  • TABLE 214 FRANCE: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019-2023 (USD MILLION)
  • TABLE 215 FRANCE: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 216 FRANCE: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2019-2023 (USD MILLION)
  • TABLE 217 FRANCE: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 218 FRANCE: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019-2023 (USD MILLION)
  • TABLE 219 FRANCE: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 220 FRANCE: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019-2023 (USD MILLION)
  • TABLE 221 FRANCE: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 222 FRANCE: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2019-2023 (USD MILLION)
  • TABLE 223 FRANCE: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2024-2029 (USD MILLION)
  • TABLE 224 FRANCE: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2019-2023 (USD MILLION)
  • TABLE 225 FRANCE: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2024-2029 (USD MILLION)
  • TABLE 226 FRANCE: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2019-2023 (USD MILLION)
  • TABLE 227 FRANCE: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2024-2029 (USD MILLION)
  • TABLE 228 SPAIN: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2019-2023 (USD MILLION)
  • TABLE 229 SPAIN: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2024-2029 (USD MILLION)
  • TABLE 230 SPAIN: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019-2023 (USD MILLION)
  • TABLE 231 SPAIN: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 232 SPAIN: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2019-2023 (USD MILLION)
  • TABLE 233 SPAIN: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 234 SPAIN: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019-2023 (USD MILLION)
  • TABLE 235 SPAIN: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 236 SPAIN: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019-2023 (USD MILLION)
  • TABLE 237 SPAIN: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 238 SPAIN: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2019-2023 (USD MILLION)
  • TABLE 239 SPAIN: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2024-2029 (USD MILLION)
  • TABLE 240 SPAIN: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2019-2023 (USD MILLION)
  • TABLE 241 SPAIN: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2024-2029 (USD MILLION)
  • TABLE 242 SPAIN: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2019-2023 (USD MILLION)
  • TABLE 243 SPAIN: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2024-2029 (USD MILLION)
  • TABLE 244 ITALY: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2019-2023 (USD MILLION)
  • TABLE 245 ITALY: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2024-2029 (USD MILLION)
  • TABLE 246 ITALY: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019-2023 (USD MILLION)
  • TABLE 247 ITALY: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 248 ITALY: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2019-2023 (USD MILLION)
  • TABLE 249 ITALY: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 250 ITALY: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019-2023 (USD MILLION)
  • TABLE 251 ITALY: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 252 ITALY: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019-2023 (USD MILLION)
  • TABLE 253 ITALY: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 254 ITALY: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2019-2023 (USD MILLION)
  • TABLE 255 ITALY: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2024-2029 (USD MILLION)
  • TABLE 256 ITALY: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2019-2023 (USD MILLION)
  • TABLE 257 ITALY: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2024-2029 (USD MILLION)
  • TABLE 258 ITALY: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2019-2023 (USD MILLION)
  • TABLE 259 ITALY: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2024-2029 (USD MILLION)
  • TABLE 260 REST OF EUROPE: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2019-2023 (USD MILLION)
  • TABLE 261 REST OF EUROPE: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2024-2029 (USD MILLION)
  • TABLE 262 REST OF EUROPE: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019-2023 (USD MILLION)
  • TABLE 263 REST OF EUROPE: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 264 REST OF EUROPE INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2019-2023 (USD MILLION)
  • TABLE 265 REST OF EUROPE: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 266 REST OF EUROPE: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019-2023 (USD MILLION)
  • TABLE 267 REST OF EUROPE: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 268 REST OF EUROPE: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019-2023 (USD MILLION)
  • TABLE 269 REST OF EUROPE: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 270 REST OF EUROPE: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2019-2023 (USD MILLION)
  • TABLE 271 REST OF EUROPE: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2024-2029 (USD MILLION)
  • TABLE 272 REST OF EUROPE: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2019-2023 (USD MILLION)
  • TABLE 273 REST OF EUROPE: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2024-2029 (USD MILLION)
  • TABLE 274 REST OF EUROPE: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2019-2023 (USD MILLION)
  • TABLE 275 REST OF EUROPE: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2024-2029 (USD MILLION)
  • TABLE 276 ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET, BY COUNTRY, 2019-2023 (USD MILLION)
  • TABLE 277 ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET, BY COUNTRY, 2024-2029 (USD MILLION)
  • TABLE 278 ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2019-2023 (USD MILLION)
  • TABLE 279 ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2024-2029 (USD MILLION)
  • TABLE 280 ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019-2023 (USD MILLION)
  • TABLE 281 ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 282 ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2019-2023 (USD MILLION)
  • TABLE 283 ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 284 ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019-2023 (USD MILLION)
  • TABLE 285 ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 286 ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019-2023 (USD MILLION)
  • TABLE 287 ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 288 ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2019-2023 (USD MILLION)
  • TABLE 289 ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2024-2029 (USD MILLION)
  • TABLE 290 ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2019-2023 (USD MILLION)
  • TABLE 291 ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2024-2029 (USD MILLION)
  • TABLE 292 ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2019-2023 (USD MILLION)
  • TABLE 293 ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2024-2029 (USD MILLION)
  • TABLE 294 JAPAN: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2019-2023 (USD MILLION)
  • TABLE 295 JAPAN: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2024-2029 (USD MILLION)
  • TABLE 296 JAPAN: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019-2023 (USD MILLION)
  • TABLE 297 JAPAN: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 298 JAPAN: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2019-2023 (USD MILLION)
  • TABLE 299 JAPAN: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 300 JAPAN: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019-2023 (USD MILLION)
  • TABLE 301 JAPAN: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 302 JAPAN: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019-2023 (USD MILLION)
  • TABLE 303 JAPAN: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 304 JAPAN: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2019-2023 (USD MILLION)
  • TABLE 305 JAPAN: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2024-2029 (USD MILLION)
  • TABLE 306 JAPAN: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2019-2023 (USD MILLION)
  • TABLE 307 JAPAN: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2024-2029 (USD MILLION)
  • TABLE 308 JAPAN: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2019-2023 (USD MILLION)
  • TABLE 309 JAPAN: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2024-2029 (USD MILLION)
  • TABLE 310 CHINA: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2019-2023 (USD MILLION)
  • TABLE 311 CHINA: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2024-2029 (USD MILLION)
  • TABLE 312 CHINA: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019-2023 (USD MILLION)
  • TABLE 313 CHINA: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 314 CHINA: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2019-2023 (USD MILLION)
  • TABLE 315 CHINA: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 316 CHINA: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019-2023 (USD MILLION)
  • TABLE 317 CHINA: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 318 CHINA: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019-2023 (USD MILLION)
  • TABLE 319 CHINA: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 320 CHINA: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2019-2023 (USD MILLION)
  • TABLE 321 CHINA: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2024-2029 (USD MILLION)
  • TABLE 322 CHINA: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2019-2023 (USD MILLION)
  • TABLE 323 CHINA: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2024-2029 (USD MILLION)
  • TABLE 324 CHINA: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2019-2023 (USD MILLION)
  • TABLE 325 CHINA: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2024-2029 (USD MILLION)
  • TABLE 326 INDIA: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2019-2023 (USD MILLION)
  • TABLE 327 INDIA: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2024-2029 (USD MILLION)
  • TABLE 328 INDIA: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019-2023 (USD MILLION)
  • TABLE 329 INDIA: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 330 INDIA: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2019-2023 (USD MILLION)
  • TABLE 331 INDIA: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 332 INDIA: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019-2023 (USD MILLION)
  • TABLE 333 INDIA: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 334 INDIA: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019-2023 (USD MILLION)
  • TABLE 335 INDIA: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 336 INDIA: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2019-2023 (USD MILLION)
  • TABLE 337 INDIA: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2024-2029 (USD MILLION)
  • TABLE 338 INDIA: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2019-2023 (USD MILLION)
  • TABLE 339 INDIA: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2024-2029 (USD MILLION)
  • TABLE 340 INDIA: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2019-2023 (USD MILLION)
  • TABLE 341 INDIA: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2024-2029 (USD MILLION)
  • TABLE 342 AUSTRALIA: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2019-2023 (USD MILLION)
  • TABLE 343 AUSTRALIA: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2024-2029 (USD MILLION)
  • TABLE 344 AUSTRALIA: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019-2023 (USD MILLION)
  • TABLE 345 AUSTRALIA: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 346 AUSTRALIA: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2019-2023 (USD MILLION)
  • TABLE 347 AUSTRALIA: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 348 AUSTRALIA: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019-2023 (USD MILLION)
  • TABLE 349 AUSTRALIA: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 350 AUSTRALIA: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019-2023 (USD MILLION)
  • TABLE 351 AUSTRALIA: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 352 AUSTRALIA: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2019-2023 (USD MILLION)
  • TABLE 353 AUSTRALIA: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2024-2029 (USD MILLION)
  • TABLE 354 AUSTRALIA: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2019-2023 (USD MILLION)
  • TABLE 355 AUSTRALIA: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2024-2029 (USD MILLION)
  • TABLE 356 AUSTRALIA: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2019-2023 (USD MILLION)
  • TABLE 357 AUSTRALIA: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2024-2029 (USD MILLION)
  • TABLE 358 SOUTH KOREA: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2019-2023 (USD MILLION)
  • TABLE 359 SOUTH KOREA: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2024-2029 (USD MILLION)
  • TABLE 360 SOUTH KOREA: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019-2023 (USD MILLION)
  • TABLE 361 SOUTH KOREA: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 362 SOUTH KOREA: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2019-2023 (USD MILLION)
  • TABLE 363 SOUTH KOREA: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 364 SOUTH KOREA: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019-2023 (USD MILLION)
  • TABLE 365 SOUTH KOREA: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 366 SOUTH KOREA: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019-2023 (USD MILLION)
  • TABLE 367 SOUTH KOREA: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 368 SOUTH KOREA: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2019-2023 (USD MILLION)
  • TABLE 369 SOUTH KOREA: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2024-2029 (USD MILLION)
  • TABLE 370 SOUTH KOREA: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2019-2023 (USD MILLION)
  • TABLE 371 SOUTH KOREA: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2024-2029 (USD MILLION)
  • TABLE 372 SOUTH KOREA: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2019-2023 (USD MILLION)
  • TABLE 373 SOUTH KOREA: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2024-2029 (USD MILLION)
  • TABLE 374 REST OF ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2019-2023 (USD MILLION)
  • TABLE 375 REST OF ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2024-2029 (USD MILLION)
  • TABLE 376 REST OF ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019-2023 (USD MILLION)
  • TABLE 377 REST OF ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 378 REST OF ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2019-2023 (USD MILLION)
  • TABLE 379 REST OF ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 380 REST OF ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019-2023 (USD MILLION)
  • TABLE 381 REST OF ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 382 REST OF ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019-2023 (USD MILLION)
  • TABLE 383 REST OF ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 384 REST OF ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2019-2023 (USD MILLION)
  • TABLE 385 REST OF ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2024-2029 (USD MILLION)
  • TABLE 386 REST OF ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2019-2023 (USD MILLION)
  • TABLE 387 REST OF ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2024-2029 (USD MILLION)
  • TABLE 388 REST OF ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2019-2023 (USD MILLION)
  • TABLE 389 REST OF ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2024-2029 (USD MILLION)
  • TABLE 390 LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY COUNTRY, 2019-2023 (USD MILLION)
  • TABLE 391 LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY COUNTRY, 2024-2029 (USD MILLION)
  • TABLE 392 LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2019-2023 (USD MILLION)
  • TABLE 393 LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2024-2029 (USD MILLION)
  • TABLE 394 LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019-2023 (USD MILLION)
  • TABLE 395 LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 396 LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2019-2023 (USD MILLION)
  • TABLE 397 LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 398 LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019-2023 (USD MILLION)
  • TABLE 399 LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 400 LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019-2023 (USD MILLION)
  • TABLE 401 LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 402 LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2019-2023 (USD MILLION)
  • TABLE 403 LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2024-2029 (USD MILLION)
  • TABLE 404 LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2019-2023 (USD MILLION)
  • TABLE 405 LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2024-2029 (USD MILLION)
  • TABLE 406 LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2019-2023 (USD MILLION)
  • TABLE 407 LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2024-2029 (USD MILLION)
  • TABLE 408 BRAZIL: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2019-2023 (USD MILLION)
  • TABLE 409 BRAZIL: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2024-2029 (USD MILLION)
  • TABLE 410 BRAZIL: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019-2023 (USD MILLION)
  • TABLE 411 BRAZIL: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 412 BRAZIL: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2019-2023 (USD MILLION)
  • TABLE 413 BRAZIL: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 414 BRAZIL: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019-2023 (USD MILLION)
  • TABLE 415 BRAZIL: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 416 BRAZIL: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019-2023 (USD MILLION)
  • TABLE 417 BRAZIL: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 418 BRAZIL: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2019-2023 (USD MILLION)
  • TABLE 419 BRAZIL: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2024-2029 (USD MILLION)
  • TABLE 420 BRAZIL: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2019-2023 (USD MILLION)
  • TABLE 421 BRAZIL: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2024-2029 (USD MILLION)
  • TABLE 422 BRAZIL: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2019-2023 (USD MILLION)
  • TABLE 423 BRAZIL: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2024-2029 (USD MILLION)
  • TABLE 424 MEXICO: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2019-2023 (USD MILLION)
  • TABLE 425 MEXICO: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2024-2029 (USD MILLION)
  • TABLE 426 MEXICO: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019-2023 (USD MILLION)
  • TABLE 427 MEXICO: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 428 MEXICO: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2019-2023 (USD MILLION)
  • TABLE 429 MEXICO: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 430 MEXICO: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019-2023 (USD MILLION)
  • TABLE 431 MEXICO: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 432 MEXICO: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019-2023 (USD MILLION)
  • TABLE 433 MEXICO: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 434 MEXICO: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2019-2023 (USD MILLION)
  • TABLE 435 MEXICO: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2024-2029 (USD MILLION)
  • TABLE 436 MEXICO: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2019-2023 (USD MILLION)
  • TABLE 437 MEXICO: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2024-2029 (USD MILLION)
  • TABLE 438 MEXICO: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2019-2023 (USD MILLION)
  • TABLE 439 MEXICO: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2024-2029 (USD MILLION)
  • TABLE 440 REST OF LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2019-2023 (USD MILLION)
  • TABLE 441 REST OF LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2024-2029 (USD MILLION)
  • TABLE 442 REST OF LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019-2023 (USD MILLION)
  • TABLE 443 REST OF LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 444 REST OF LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2019-2023 (USD MILLION)
  • TABLE 445 REST OF LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 446 REST OF LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019-2023 (USD MILLION)
  • TABLE 447 REST OF LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 448 REST OF LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019-2023 (USD MILLION)
  • TABLE 449 REST OF LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 450 REST OF LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2019-2023 (USD MILLION)
  • TABLE 451 REST OF LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2024-2029 (USD MILLION)
  • TABLE 452 REST OF LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2019-2023 (USD MILLION)
  • TABLE 453 REST OF LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2024-2029 (USD MILLION)
  • TABLE 454 REST OF LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2019-2023 (USD MILLION)
  • TABLE 455 REST OF LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2024-2029 (USD MILLION)
  • TABLE 456 MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET, BY COUNTRY, 2019-2023 (USD MILLION)
  • TABLE 457 MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET, BY COUNTRY, 2024-2029 (USD MILLION)
  • TABLE 458 MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2019-2023 (USD MILLION)
  • TABLE 459 MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2024-2029 (USD MILLION)
  • TABLE 460 MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019-2023 (USD MILLION)
  • TABLE 461 MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 462 MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2019-2023 (USD MILLION)
  • TABLE 463 MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 464 MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019-2023 (USD MILLION)
  • TABLE 465 MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 466 MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019-2023 (USD MILLION)
  • TABLE 467 MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 468 MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2019-2023 (USD MILLION)
  • TABLE 469 MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2024-2029 (USD MILLION)
  • TABLE 470 MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2019-2023 (USD MILLION)
  • TABLE 471 MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2024-2029 (USD MILLION)
  • TABLE 472 MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2019-2023 (USD MILLION)
  • TABLE 473 MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2024-2029 (USD MILLION)
  • TABLE 474 GCC COUNTRIES: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2019-2023 (USD MILLION)
  • TABLE 475 GCC COUNTRIES: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2024-2029 (USD MILLION)
  • TABLE 476 GCC COUNTRIES: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019-2023 (USD MILLION)
  • TABLE 477 GCC COUNTRIES: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 478 GCC COUNTRIES: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2019-2023 (USD MILLION)
  • TABLE 479 GCC COUNTRIES: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 480 GCC COUNTRIES: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019-2023 (USD MILLION)
  • TABLE 481 GCC COUNTRIES: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 482 GCC COUNTRIES: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019-2023 (USD MILLION)
  • TABLE 483 GCC COUNTRIES: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 484 GCC COUNTRIES: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2019-2023 (USD MILLION)
  • TABLE 485 GCC COUNTRIES: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2024-2029 (USD MILLION)
  • TABLE 486 GCC COUNTRIES: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2019-2023 (USD MILLION)
  • TABLE 487 GCC COUNTRIES: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2024-2029 (USD MILLION)
  • TABLE 488 GCC COUNTRIES: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2019-2023 (USD MILLION)
  • TABLE 489 GCC COUNTRIES: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2024-2029 (USD MILLION)
  • TABLE 490 REST OF MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2019-2023 (USD MILLION)
  • TABLE 491 REST OF MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2024-2029 (USD MILLION)
  • TABLE 492 REST OF MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019-2023 (USD MILLION)
  • TABLE 493 REST OF MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 494 REST OF MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2019-2023 (USD MILLION)
  • TABLE 495 REST OF MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 496 REST OF MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019-2023 (USD MILLION)
  • TABLE 497 REST OF MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 498 REST OF MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019-2023 (USD MILLION)
  • TABLE 499 REST OF MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 500 REST OF MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2019-2023 (USD MILLION)
  • TABLE 501 REST OF MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2024-2029 (USD MILLION)
  • TABLE 502 REST OF MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2019-2023 (USD MILLION)
  • TABLE 503 REST OF MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2024-2029 (USD MILLION)
  • TABLE 504 REST OF MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2019-2023 (USD MILLION)
  • TABLE 505 REST OF MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2024-2029 (USD MILLION)
  • TABLE 506 STRATEGIES ADOPTED BY KEY PLAYERS IN INTERVENTIONAL ONCOLOGY MARKET, JANUARY 2021-DECEMBER 2024
  • TABLE 507 INTERVENTIONAL ONCOLOGY MARKET: DEGREE OF COMPETITION
  • TABLE 508 INTERVENTIONAL ONCOLOGY MARKET: REGION FOOTPRINT
  • TABLE 509 INTERVENTIONAL ONCOLOGY MARKET: DEVICES & CONSUMABLES FOOTPRINT
  • TABLE 510 INTERVENTIONAL ONCOLOGY MARKET: CANCER TYPE FOOTPRINT
  • TABLE 511 INTERVENTIONAL ONCOLOGY MARKET: PROCEDURE FOOTPRINT
  • TABLE 512 INTERVENTIONAL ONCOLOGY MARKET: END USER FOOTPRINT
  • TABLE 513 INTERVENTIONAL ONCOLOGY MARKET: DETAILED LIST OF KEY STARTUPS/ SMES, 2023
  • TABLE 514 INTERVENTIONAL ONCOLOGY MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
  • TABLE 515 INTERVENTIONAL ONCOLOGY MARKET: PRODUCT & SERVICE LAUNCHES AND APPROVALS, JANUARY 2021-DECEMBER 2024
  • TABLE 516 INTERVENTIONAL ONCOLOGY MARKET: DEALS, JANUARY 2021-DECEMBER 2024
  • TABLE 517 INTERVENTIONAL ONCOLOGY MARKET: EXPANSIONS, JANUARY 2021-DECEMBER 2024
  • TABLE 518 SIEMENS HEALTHINEERS AG (VARIAN): COMPANY OVERVIEW
  • TABLE 519 SIEMENS HEALTHINEERS AG (VARIAN): PRODUCTS/SOLUTIONS/ SERVICES OFFERED
  • TABLE 520 SIEMENS HEALTHINEERS AG (VARIAN): PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-DECEMBER 2024
  • TABLE 521 SIEMENS HEALTHINEERS AG (VARIAN): DEALS, JANUARY 2021-DECEMBER 2024
  • TABLE 522 BOSTON SCIENTIFIC CORPORATION: COMPANY OVERVIEW
  • TABLE 523 BOSTON SCIENTIFIC CORPORATION: PRODUCTS/SOLUTIONS/SERVICES OFFERED
  • TABLE 524 BOSTON SCIENTIFIC CORPORATION: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-DECEMBER 2024
  • TABLE 525 BOSTON SCIENTIFIC CORPORATION: DEALS, JANUARY 2021-DECEMBER 2024
  • TABLE 526 MEDTRONIC: COMPANY OVERVIEW
  • TABLE 527 MEDTRONIC: PRODUCTS/SOLUTIONS/SERVICES OFFERED
  • TABLE 528 TERUMO CORPORATION: COMPANY OVERVIEW
  • TABLE 529 TERUMO CORPORATION: PRODUCTS/SOLUTIONS/SERVICES OFFERED
  • TABLE 530 TERUMO CORPORATION: EXPANSIONS, JANUARY 2021- DECEMBER 2024
  • TABLE 531 MERIT MEDICAL SYSTEMS: COMPANY OVERVIEW
  • TABLE 532 MERIT MEDICAL SYSTEMS: PRODUCTS/SOLUTIONS/SERVICES OFFERED
  • TABLE 533 MERIT MEDICAL SYSTEMS: EXPANSIONS, JANUARY 2021- DECEMBER 2024
  • TABLE 534 JOHNSON & JOHNSON MEDTECH (ETHICON): COMPANY OVERVIEW
  • TABLE 535 JOHNSON & JOHNSON MEDTECH (ETHICON): PRODUCTS/SOLUTIONS/ SERVICES OFFERED
  • TABLE 536 TELEFLEX INCORPORATED: COMPANY OVERVIEW
  • TABLE 537 TELEFLEX INCORPORATED: PRODUCTS/SOLUTIONS/SERVICES OFFERED
  • TABLE 538 ANGIODYNAMICS: COMPANY OVERVIEW
  • TABLE 539 ANGIODYNAMICS: PRODUCTS/SOLUTIONS/SERVICES OFFERED
  • TABLE 540 ANGIODYNAMICS: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-DECEMBER 2024
  • TABLE 541 STRYKER: COMPANY OVERVIEW
  • TABLE 542 STRYKER: PRODUCTS/SOLUTIONS/SERVICES OFFERED
  • TABLE 543 IMBIOTECHNOLOGIES LTD.: COMPANY OVERVIEW
  • TABLE 544 IMBIOTECHNOLOGIES LTD.: PRODUCTS/SOLUTIONS/SERVICES OFFERED
  • TABLE 545 COOK: COMPANY OVERVIEW
  • TABLE 546 COOK: PRODUCTS/SOLUTIONS/SERVICES OFFERED
  • TABLE 547 ICECURE MEDICAL: COMPANY OVERVIEW
  • TABLE 548 ICECURE MEDICAL: PRODUCTS/SOLUTIONS/SERVICES OFFERED
  • TABLE 549 ICECURE MEDICAL LTD.: PRODUCT APPROVALS
  • TABLE 550 ICECURE MEDICAL LTD.: DEALS
  • TABLE 551 MEDWAVES, INC.: COMPANY OVERVIEW
  • TABLE 552 MEDWAVES INC.: PRODUCTS/SOLUTIONS/SERVICES OFFERED
  • TABLE 553 PROFOUND MEDICAL: COMPANY OVERVIEW
  • TABLE 554 PROFOUND MEDICAL: PRODUCTS/SOLUTIONS/SERVICES OFFERED
  • TABLE 555 RF MEDICAL CO., LTD.: COMPANY OVERVIEW
  • TABLE 556 RF MEDICAL CO., LTD.: PRODUCTS/SOLUTIONS/SERVICES OFFERED
  • TABLE 557 MINIMAX MEDICAL LIMITED: COMPANY OVERVIEW
  • TABLE 558 MINIMAX MEDICAL LIMITED: PRODUCTS/SOLUTIONS/SERVICES OFFERED
  • TABLE 559 ABK BIOMEDICAL INC.: COMPANY OVERVIEW
  • TABLE 560 ABK BIOMEDICAL INC.: PRODUCTS/SOLUTIONS/SERVICES OFFERED
  • TABLE 561 OLYMPUS CORPORATION: COMPANY OVERVIEW
  • TABLE 562 OLYMPUS CORPORATION: PRODUCTS/SOLUTIONS/SERVICES OFFERED
  • TABLE 563 SURGNOVA: COMPANY OVERVIEW
  • TABLE 564 SURGNOVA: PRODUCTS/SOLUTIONS/SERVICES OFFERED
  • TABLE 565 STARMED AMERICA: COMPANY OVERVIEW
  • TABLE 566 STARMED AMERICA: PRODUCTS/SOLUTIONS/SERVICES OFFERED
  • TABLE 567 SIRTEX SIR-SPHERES PTY LTD.: COMPANY OVERVIEW
  • TABLE 568 GUERBET: COMPANY OVERVIEW
  • TABLE 569 ACCURAY: COMPANY OVERVIEW
  • TABLE 570 EMBOLX, INC.: COMPANY OVERVIEW
  • TABLE 571 SONABLATE CORP.: COMPANY OVERVIEW

List of Figures

  • FIGURE 1 INTERVENTIONAL ONCOLOGY MARKET SEGMENTATION
  • FIGURE 2 RESEARCH DESIGN
  • FIGURE 3 PRIMARY SOURCES
  • FIGURE 4 BREAKDOWN OF INTERVIEWS WITH EXPERTS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
  • FIGURE 5 BREAKDOWN OF INTERVIEWS WITH EXPERTS (SUPPLY SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 6 BREAKDOWN OF INTERVIEWS WITH EXPERTS (DEMAND SIDE): BY END USER, DESIGNATION, AND REGION
  • FIGURE 7 SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
  • FIGURE 8 REVENUE SHARE ANALYSIS ILLUSTRATION: SIEMENS HEALTHINEERS AG (2023)
  • FIGURE 9 SUPPLY-SIDE MARKET SIZE ESTIMATION: INTERVENTIONAL ONCOLOGY MARKET (2023)
  • FIGURE 10 TOP-DOWN APPROACH
  • FIGURE 11 ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES (2024-2029)
  • FIGURE 12 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
  • FIGURE 13 DATA TRIANGULATION METHODOLOGY
  • FIGURE 14 EMBOLIZATION DEVICES SEGMENT TO DOMINATE INTERVENTIONAL ONCOLOGY MARKET DURING FORECAST PERIOD (USD MILLION)
  • FIGURE 15 LIVER CANCER TYPE SEGMENT TO LEAD MARKET DURING FORECAST PERIOD (USD MILLION)
  • FIGURE 16 THERMAL TUMOR ABLATION SEGMENT TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD (USD MILLION)
  • FIGURE 17 HOSPITALS SEGMENT TO DOMINATE INTERVENTIONAL ONCOLOGY MARKET DURING FORECAST PERIOD (USD MILLION)
  • FIGURE 18 NORTH AMERICA ACCOUNTED FOR LARGEST SHARE OF INTERVENTIONAL ONCOLOGY MARKET IN 2023
  • FIGURE 19 GROWING DEMAND FOR INTERVENTIONAL ONCOLOGY TO DRIVE MARKET
  • FIGURE 20 EMBOLIZATION DEVICES ACCOUNTED FOR LARGEST SHARE OF INTERVENTIONAL ONCOLOGY MARKET IN 2023
  • FIGURE 21 CHINA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD
  • FIGURE 22 NORTH AMERICA TO DOMINATE MARKET DURING FORECAST PERIOD
  • FIGURE 23 EMERGING MARKETS TO REGISTER HIGHER GROWTH RATES DURING FORECAST PERIOD
  • FIGURE 24 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES IN INTERVENTIONAL ONCOLOGY MARKET
  • FIGURE 25 VALUE CHAIN ANALYSIS: MAXIMUM VALUE ADDED DURING MANUFACTURING PHASE
  • FIGURE 26 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF EMBOLIZATION DEVICES, ABLATION DEVICES, AND SUPPORT DEVICES
  • FIGURE 27 KEY BUYING CRITERIA FOR EMBOLIZATION DEVICES, ABLATION DEVICES, AND SUPPORT DEVICES
  • FIGURE 28 PREMARKET NOTIFICATION: 510(K) APPROVALS FOR MEDICAL DEVICES
  • FIGURE 29 CANADA: REGULATORY APPROVAL PROCESS FOR MEDICAL DEVICES
  • FIGURE 30 EUROPE: CE APPROVAL PROCESS FOR MEDICAL DEVICES
  • FIGURE 31 REVENUE SHIFT IN INTERVENTIONAL ONCOLOGY MARKET
  • FIGURE 32 PATENT PUBLICATION TRENDS, JANUARY 2014-DECEMBER 2024
  • FIGURE 33 TOP PATENT APPLICANTS AND OWNERS (COMPANIES/INSTITUTES) FOR INTERVENTIONAL ONCOLOGY, JANUARY 2014-DECEMBER 2024
  • FIGURE 34 TOP APPLICANT JURISDICTIONS FOR INTERVENTIONAL ONCOLOGY PATENTS, JANUARY 2014-DECEMBER 2024
  • FIGURE 35 AVERAGE SELLING PRICE OF INTERVENTIONAL ONCOLOGY DEVICES, BY KEY PLAYER, 2023
  • FIGURE 36 END USER EXPECTATIONS IN EMBOLIZATION DEVICES, ABLATION DEVICES, AND SUPPORT DEVICES
  • FIGURE 37 INTERVENTIONAL ONCOLOGY MARKET: ECOSYSTEM
  • FIGURE 38 INTERVENTIONAL ONCOLOGY MARKET: SUPPLY CHAIN ANALYSIS
  • FIGURE 39 ADJACENT MARKETS TO INTERVENTIONAL ONCOLOGY MARKET
  • FIGURE 40 INVESTMENT/VENTURE CAPITAL SCENARIO IN INTERVENTIONAL ONCOLOGY MARKET, 2020-2023
  • FIGURE 41 CHINA TO GROW AT HIGHEST CAGR IN INTERVENTIONAL ONCOLOGY MARKET DURING FORECAST PERIOD
  • FIGURE 42 NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET SNAPSHOT
  • FIGURE 43 EUROPE: INTERVENTIONAL ONCOLOGY MARKET SNAPSHOT
  • FIGURE 44 ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET SNAPSHOT
  • FIGURE 45 REVENUE SHARE ANALYSIS OF KEY PLAYERS IN INTERVENTIONAL ONCOLOGY MARKET,2019-2023
  • FIGURE 46 INTERVENTIONAL ONCOLOGY MARKET SHARE ANALYSIS, BY KEY PLAYER, 2023
  • FIGURE 47 INTERVENTIONAL ONCOLOGY MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
  • FIGURE 48 INTERVENTIONAL ONCOLOGY MARKET: COMPANY FOOTPRINT
  • FIGURE 49 INTERVENTIONAL ONCOLOGY MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
  • FIGURE 50 EV/EBITDA OF KEY VENDORS
  • FIGURE 51 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
  • FIGURE 52 INTERVENTIONAL ONCOLOGY MARKET: COMPARATIVE BRAND ANALYSIS
  • FIGURE 53 SIEMENS HEALTHINEERS AG (VARIAN): COMPANY SNAPSHOT (2024)
  • FIGURE 54 BOSTON SCIENTIFIC CORPORATION: COMPANY SNAPSHOT (2023)
  • FIGURE 55 MEDTRONIC: COMPANY SNAPSHOT (2024)
  • FIGURE 56 TERUMO CORPORATION: COMPANY SNAPSHOT (2024)
  • FIGURE 57 MERIT MEDICAL SYSTEMS: COMPANY SNAPSHOT (2023)
  • FIGURE 58 JOHNSON & JOHNSON MEDTECH (ETHICON): COMPANY SNAPSHOT (2023)
  • FIGURE 59 TELEFLEX INCORPORATED: COMPANY SNAPSHOT (2023)
  • FIGURE 60 ANGIODYNAMICS: COMPANY SNAPSHOT (2024)
  • FIGURE 61 STRYKER: COMPANY SNAPSHOT (2023)
  • FIGURE 62 ICECURE MEDICAL LTD.: COMPANY SNAPSHOT (2023)
  • FIGURE 63 OLYMPUS CORPORATION: COMPANY SNAPSHOT (2024)